Johnson & Johnson (NYSE:JNJ) today announced that group worldwide chairwoman Sandra Peterson will retire from their position, effective October 1, alongside a number of appointments to its executive roster.
Peterson joined J&J in December 2012, and had previously operated as chair & CEO of Bayer CropScience AG in Germany, CEO of Bayer Medical Care and prez of Bayer HealthCare AG’s diabetes care division, New Brunswick, N.J.-based J&J said.
Currently, Peterson serves on the board of Microsoft, as a member of the board of trustees for the Institute for Advanced Study and as a Trustee of The American Academy in Berlin.
“Sandi’s global mindset and passion for people have been hallmarks of her career, and influenced the work she’s done to better enable us to meet the needs of patients and consumers around the world. Sandi has been a dynamic business partner and inspirational leader, and I wish her all the best in this new chapter of her life,” chair & CEO Alex Gorsky said in a press release.
Johnson & Johnson also released a number of adjustments it’s making to its executive roster, including appointing exec VP and pharma worldwide chair Joaquin Duato and chief scientific officer and exec VP Dr. Paul Stoffels as vice chairs of its executive committee.
The company said that it appointed consumer medical devices company group chair Ashley McEvoy as exec VP and worldwide chair of its medical devices division and that it lifted current Americas pharmaceuticals group chair Jennifer Taubert to the role of exec VP and pharmaceuticals worldwide chair.
Current supply chain worldwide VP Kathy Wengel was lifted to chief global supply chain officer and global corporate affairs and chief communications officer Michael Sneed was appointed as exec VP alongside their existing positions.
All of the individuals were also named to the company’s executive committee, Johnson & Johnson said.
“These appointments recognize the enormous talent among the senior leadership team of Johnson & Johnson, and will ensure our continued focus on delivering on our commitments to patients, consumers, employees, our communities and our shareholders,” Gorsky said in a prepared statement.
Earlier this week, Johnson & Johnson opened its latest life science incubator in New York City